PointState Capital’s Coherus Oncology CHRS Stock Holding History

PointState Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-421,300	Closed	-$8.91M	–	143
2017 Q1	$8.91M	Buy	+421,300	New	+$10.4M	0.09%	105

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital's CHRS Position: Q2 2017 in Review

PointState Capital sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 421,300 shares — an estimated $8.91M sold.

PointState Capital first reported a position in CHRS in Q1 2017 and held it in 1 quarter. The position peaked at $8.91M in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

PointState Capital reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
PointState Capital sold 421,300 Coherus Oncology shares in Q2 2017, an estimated $8.91M.
PointState Capital first reported a position in Coherus Oncology in Q1 2017 and held it in 1 quarter.
PointState Capital's Coherus Oncology position peaked at $8.91M in Q1 2017.
106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on PointState Capital's 13F filing for Q2 2017, filed 14 Aug 2017.